Giovanni Mantovani

Summary

Affiliation: University of Cagliari
Country: Italy

Publications

  1. ncbi request reprint Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity
    Giovanni Mantovani
    Department of Medical Oncology, Policlinico Universitario, University of Cagliari, Cagliari 09042, Italy
    Int J Oncol 20:419-27. 2002
  2. ncbi request reprint A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress
    Giovanni Mantovani
    Cattedra e Divisione di Oncologia Medica, Universita di Cagliari, Policlinico Universitario, Presidio di Monserrato, SS 554, km 4 500, 09042 Monserrato, Cagliari, Italy
    Cancer Epidemiol Biomarkers Prev 15:1030-4. 2006
  3. ncbi request reprint Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Calgliari, Italy
    J Cell Mol Med 6:570-82. 2002
  4. ncbi request reprint The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Free Radic Res 37:213-23. 2003
  5. ncbi request reprint Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    J Environ Pathol Toxicol Oncol 22:17-28. 2003
  6. ncbi request reprint Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes
    Giovanni Mantovani
    Cattedra e Divisione di Oncologia Medica, Policlinico Universitario di Cagliari, Presidio di Monserrato, Strada Statale 554, Bivio Sestu, 09042 Monserrato, Cagliari, Italy
    Oncol Rep 10:759-66. 2003
  7. ncbi request reprint Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Oncol Rep 11:197-206. 2004
  8. ncbi request reprint Cancer-related cachexia and oxidative stress: beyond current therapeutic options
    Giovanni Mantovani
    Cattedra e Divisione di Oncologia Medica, Università di Cagliari Policlinico Universitario, Presidio di Monserrato, Italy
    Expert Rev Anticancer Ther 3:381-92. 2003
  9. ncbi request reprint Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress
    Giovanni Mantovani
    Department of Medical Oncology, Policlinico Universitario, University of Cagliari, Strada Statale 554 bivio Sestu, 09042 Monserrato, Italy
    J Mol Med (Berl) 81:664-73. 2003
  10. ncbi request reprint Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    J Exp Ther Oncol 3:205-19. 2003

Collaborators

Detail Information

Publications59

  1. ncbi request reprint Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity
    Giovanni Mantovani
    Department of Medical Oncology, Policlinico Universitario, University of Cagliari, Cagliari 09042, Italy
    Int J Oncol 20:419-27. 2002
    ..For these reasons, this regimen could not be recommended for a phase III randomized study...
  2. ncbi request reprint A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress
    Giovanni Mantovani
    Cattedra e Divisione di Oncologia Medica, Universita di Cagliari, Policlinico Universitario, Presidio di Monserrato, SS 554, km 4 500, 09042 Monserrato, Cagliari, Italy
    Cancer Epidemiol Biomarkers Prev 15:1030-4. 2006
    ..Patients and..
  3. ncbi request reprint Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Calgliari, Italy
    J Cell Mol Med 6:570-82. 2002
    ..We also tested the reducing ability of different antioxidant agents on reactive oxygen species levels by measuring the increase in glutathione peroxidase activity, and the reduction of serum levels of IL-6 and TNF...
  4. ncbi request reprint The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Free Radic Res 37:213-23. 2003
    ..Furthermore, a correlation was shown between the Eastern Cooperative Oncology Group Performance Status of patients and blood levels of ROS, GPx activity, serum levels of proinflammatory cytokines...
  5. ncbi request reprint Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    J Environ Pathol Toxicol Oncol 22:17-28. 2003
    ..We also tested the reducing ability of different antioxidant agents on reactive oxygen species levels by measuring the increase in glutathione peroxidase activity and the reduction of serum levels of IL-6 and TNF-alpha...
  6. ncbi request reprint Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes
    Giovanni Mantovani
    Cattedra e Divisione di Oncologia Medica, Policlinico Universitario di Cagliari, Presidio di Monserrato, Strada Statale 554, Bivio Sestu, 09042 Monserrato, Cagliari, Italy
    Oncol Rep 10:759-66. 2003
    ..All patients spared organ/function. In conclusion, this regimen has been found feasible for its acceptable toxicity, particularly mucositis. However, the overall response rate and the data on survival were not satisfactory...
  7. ncbi request reprint Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Oncol Rep 11:197-206. 2004
    ....
  8. ncbi request reprint Cancer-related cachexia and oxidative stress: beyond current therapeutic options
    Giovanni Mantovani
    Cattedra e Divisione di Oncologia Medica, Università di Cagliari Policlinico Universitario, Presidio di Monserrato, Italy
    Expert Rev Anticancer Ther 3:381-92. 2003
    ..A Phase II study has been initiated and Phase III study designed...
  9. ncbi request reprint Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress
    Giovanni Mantovani
    Department of Medical Oncology, Policlinico Universitario, University of Cagliari, Strada Statale 554 bivio Sestu, 09042 Monserrato, Italy
    J Mol Med (Berl) 81:664-73. 2003
    ..Our data warrant further investigation with adequate clinical trials...
  10. ncbi request reprint Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    J Exp Ther Oncol 3:205-19. 2003
    ..Long-term combined maintenance therapy with rIL-2 + MPA + antioxidant agents is feasible, has a very low toxicity, and results in the improvement of clinical outcome, QL, and laboratory parameters...
  11. ncbi request reprint Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari Medical School, Italy
    J Exp Ther Oncol 4:69-78. 2004
    ..The mechanism of action of selenium could be to downregulate the production and release of proinflammatory cytokines, which have a role in cancer progression and particularly in the onset of cachexia...
  12. ncbi request reprint Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, 09042, Italy
    Cancer Epidemiol Biomarkers Prev 13:1651-9. 2004
    ..Cancer-related anorexia/cachexia syndrome and oxidative stress play a key role in the progression and outcome of neoplastic disease. Patients and..
  13. doi request reprint Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Nutrition 24:305-13. 2008
    ....
  14. ncbi request reprint Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs
    Giovanni Mantovani
    Department of Medcial Oncology, University of Cagliari, Policlinico Universitario, Italy
    Oncol Rep 10:197-206. 2003
    ..Moreover, the 'prophylactic' setting was demonstrated to be more effective than the 'curative' one...
  15. ncbi request reprint Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Cancer Immunol Immunother 47:149-56. 1998
    ....
  16. ncbi request reprint Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    J Mol Med (Berl) 78:554-61. 2000
    ....
  17. ncbi request reprint Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Int J Cancer 71:724-31. 1997
    ..Cell cycle analysis of cultured TALMs and PBMCs (from 3 patients) showed a significant accumulation of TALMs in the non-cycling G0/G1 cell population compared with autologous PBMCs...
  18. ncbi request reprint Managing cancer-related anorexia/cachexia
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Drugs 61:499-514. 2001
    ..There is an ongoing need for quality of life questionnaires which specifically address the most significant symptoms present in patients with CAC...
  19. ncbi request reprint Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Policlinico Universitario, 09042 Monserrato, Italy
    J Mol Med (Berl) 79:406-14. 2001
    ....
  20. ncbi request reprint Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine
    G Mantovani
    Department of Medical Oncology and Internal Medical Sciences, University of Cagliari, Cagliari, Italy
    Int J Cancer 86:842-7. 2000
    ..The results of the present study show a favorable effect of antioxidant agents ALA and NAC on several important T-cell functions in vitro in advanced-stage cancer patients...
  21. ncbi request reprint Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Int J Cancer 98:84-91. 2002
    ....
  22. ncbi request reprint Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Oncol Rep 9:887-96. 2002
    ....
  23. ncbi request reprint Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first cli
    G Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Anticancer Res 19:3495-502. 1999
    ..DEX, in the prevention of delayed N&V in patients with advanced stage head and neck squamous cell carcinoma receiving high-dose (> or = 100 mg/m2) cisplatin. This is the first report on the clinical use of TTS-F in this setting...
  24. ncbi request reprint Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy
    G Mantovani
    Cattedra e Divisione di Oncologia Medica, Universita di Cagliari, Policlinico Universitario, via S Giorgio 12, I 09124 Cagliari, Italy
    Int J Oncol 18:383-91. 2001
    ..g. lymphocytosis), are worth further study as potential markers for the major end points of cancer treatment, i.e. OS and QL, in an adequate number of patients...
  25. ncbi request reprint Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy
    Giulia Gramignano
    Department of Medical Oncology, University of Cagliari, Monserrato, Italy
    Nutrition 22:136-45. 2006
    ..It is one of the most common side effects of chemotherapy and radiotherapy. In recent studies, l-carnitine (LC) supplementation has been demonstrated to be able to improve fatigue symptoms in patients with cancer...
  26. doi request reprint Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment
    Christian Cadeddu
    Department of Cardiovascular and Neurological Sciences, University of Cagliari, Italy
    Am Heart J 160:487.e1-7. 2010
    ..Telmisartan, an angiotensin II type 1 receptor blocker, inhibits activation of superoxide sources and induces anti-inflammatory effects...
  27. doi request reprint Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Monserrato Cagliari, Italy
    Oncologist 13:1296-305. 2008
    ..The clinical meaningfulness of our findings warrants further investigations on a larger number of patients for a longer period of follow-up...
  28. doi request reprint Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome
    Clelia Madeddu
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Clin Nutr 31:176-82. 2012
    ..Secondary endpoint was: increase of physical performance tested by grip strength and 6-min walk test...
  29. pmc Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Oncologist 15:200-11. 2010
    ....
  30. ncbi request reprint Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Oncol Rep 9:661-70. 2002
    ..5 months). Moreover, the toxicity was acceptable and it was mainly hematologic. Serum levels of proinflammatory cytokines significantly decreased after treatment...
  31. doi request reprint Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    J Mol Med (Berl) 88:85-92. 2010
    ..Therefore, phase III clinical trials are warranted to test the efficacy and safety of celecoxib...
  32. ncbi request reprint Cachexia and oxidative stress in cancer: an innovative therapeutic management
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari SS 554, km 4 500, 09042 Monserrato, Cagliari, Italy
    Curr Pharm Des 18:4813-8. 2012
    ..According to this rationale, antioxidants should be included as essential components of a multitargeted combined treatment of cancer cachexia, which has been shown to be the most successful approach for this syndrome...
  33. doi request reprint Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: c
    Elena Massa
    Department of Medical Oncology, University of Cagliari, Italy
    Crit Rev Oncol Hematol 70:83-91. 2009
    ..In conclusion, single dose palonosetron (250 microg) should be considered a safe and effective second generation 5-HT(3) antagonist in the prevention of nausea and vomiting induced by HEC or MEC, irrespective of patients' age...
  34. ncbi request reprint Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers
    Giuseppe Mercuro
    Department of Cardiovascular and Neurological Sciences, University of Cagliari, Cagliari, Italy
    Oncologist 12:1124-33. 2007
    ..The clinical meaningfulness of our findings warrants further investigations in a larger number of patients for a longer period of follow-up...
  35. ncbi request reprint Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy
    Elena Massa
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Crit Rev Oncol Hematol 57:175-82. 2006
    ....
  36. ncbi request reprint Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Curr Opin Support Palliat Care 2:275-81. 2008
    ..Reported findings highlight the role of chronic inflammation and oxidative stress in the onset of cancer cachexia...
  37. doi request reprint An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: results of a phase II open study
    Elena Massa
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Crit Rev Oncol Hematol 66:75-83. 2008
    ..e whether this process might achieve a clinically meaningful impact...
  38. ncbi request reprint Multitargeted treatment of cancer cachexia
    Clelia Madeddu
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Crit Rev Oncog 17:305-14. 2012
    ....
  39. doi request reprint Medroxyprogesterone acetate in the management of cancer cachexia
    Clelia Madeddu
    Department of Medical Oncology, University of Cagliari, SS 554, km 4 500, 09042 Monserrato Cagliari, Italy
    Expert Opin Pharmacother 10:1359-66. 2009
    ....
  40. doi request reprint Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens
    Elena Massa
    Department of Medical Oncology, University of Cagliari, Italy
    Oral Oncol 46:818-21. 2010
    ..Our findings warrant further investigation in a wider patient population...
  41. doi request reprint Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Italy
    Curr Opin Support Palliat Care 4:259-65. 2010
    ..The assessment of physical activity level as an outcome measure for cachexia studies is attractive as it offers a patient-centered outcome concerned with functional status and independence...
  42. ncbi request reprint Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia
    G Mantovani
    Department of Medical Oncology, Schoool of Medicine, University of Cagliari, Italy
    Eur Rev Med Pharmacol Sci 14:292-301. 2010
    ....
  43. doi request reprint Cancer cachexia: medical management
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Support Care Cancer 18:1-9. 2010
    ....
  44. doi request reprint An update on promising agents for the treatment of cancer cachexia
    Clelia Madeddu
    Department of Medical Oncology, University of Cagliari, Italy
    Curr Opin Support Palliat Care 3:258-62. 2009
    ..The purpose of this review is to supply an update on the promising agents and/or combined approaches for the treatment of cancer cachexia...
  45. pmc Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome
    Giovanni Mantovani
    Department of Medical Oncology, University of Cagliari, Cagliari, Italy
    Drug Des Devel Ther 7:645-56. 2013
    ....
  46. ncbi request reprint A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia
    Bertram Wiedenmann
    Department of Internal Medicine, Charite, Humboldt University, Berlin, Germany
    J Support Oncol 6:18-25. 2008
    ..Adding infliximab to gemcitabine to treat cachexia in advanced pancreatic cancer patients was not associated with statistically significant differences in safety or efficacy when compared with placebo...
  47. ncbi request reprint Anthropometric measurements in non-small-cell lung cancer
    Giovanni Mantovani
    Support Care Cancer 10:439; author reply 440. 2002
  48. ncbi request reprint Does megestrol acetate down-regulate interleukin-6 in patients?
    Giovanni Mantovani
    Support Care Cancer 10:566-7; author reply 568. 2002
  49. ncbi request reprint Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. By Declan Walsh et al. Supportive Care in Cancer (2003) 11:60-62
    Giovanni Mantovani
    Support Care Cancer 11:494-5. 2003
  50. ncbi request reprint Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy
    Cristina Granetto
    Oncology Department, Azienda Ospedaliera S Croce e Carle, Cuneo, Italy
    Oncol Rep 10:1289-96. 2003
    ..These findings support the use of a fixed-dose regimen of epoetin alpha, which may offer greater convenience for physicians and patients than weight-based dosing with this agent...
  51. ncbi request reprint Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer
    Francesco Recchia
    Unita operative di Oncologia, Ospedale Civile di Avezzano, Italy
    Anticancer Res 24:1935-40. 2004
    ..To evaluate the efficacy and safety of oxaliplatin (L-OHP) fractionated over two days with bimonthly 5-fluorouracil (5-FU) and leucovorin (LV), as first-line treatment of metastatic colorectal cancer (MCC) patients...
  52. ncbi request reprint Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia
    Antonio Maccio
    Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy
    Blood 106:362-7. 2005
    ..This evidence suggests that anemia in epithelial ovarian cancer is common and its presence is related to stage of disease and markers of inflammation...
  53. ncbi request reprint Branched-chain amino acids: the best compromise to achieve anabolism?
    Alessandro Laviano
    Department of Clinical Medicine, University La Sapienza, Rome, Italy
    Curr Opin Clin Nutr Metab Care 8:408-14. 2005
    ..More effective therapies are needed to promote appetite and food intake, to preserve lean body mass, and to ameliorate patients' psychological distress...
  54. ncbi request reprint Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial
    Maria Di Bartolomeo
    Medical Oncology Unit 2, Fondazione IRCCS, Istituto Nazionale dei Tumori of Milano, Milano, Italia
    Oncology 71:341-6. 2006
    ..In this paper, we present the results of a phase III trial in which these two combinations given sequentially were compared to mitomycin C (MMC) monochemotherapy in an adjuvant setting...
  55. pmc Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
    Francesca Russo
    Medical Department, Eli Lilly Italia S p A Sesto Fiorentino FI, Italy
    BMC Cancer 8:216. 2008
    ..The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC...
  56. ncbi request reprint Relationship between body composition and cytokines in cachectic patients with chronic obstructive pulmonary disease
    Shing Shing Yeh
    J Am Geriatr Soc 51:890-1. 2003
  57. ncbi request reprint A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer
    Francesco Recchia
    Unita Operativa di Oncologia, Ospedale Civile di Avezzano, AQ, Italy
    Gynecol Oncol 106:164-9. 2007
    ..This phase II study investigated the safety and activity of PLD and LOHP used in combination to treat ROC...
  58. ncbi request reprint Stop Flow in abdominal and pelvic cancer relapses
    Rosario Vincenzo Iaffaioli
    Med Onc B INT Naples, Cagliari University, Italy
    Front Biosci 11:1284-8. 2006
    ..Stop-Flow is a safe and feasible technique very useful as a palliation treatment...
  59. ncbi request reprint Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review
    Giovanni Mantovani
    Eur J Obstet Gynecol Reprod Biol 131:238-9. 2007